Taysha Gene Therapies
Alan Boyd, B.Sc., M.B., Ch.B., FRSB, FFLM, FRCP, FFPM, is the CEO and founder of Boyd Consultants and a fellow and Immediate Past-President of the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians, UK. Professor Boyd is also a Council Member and the Independent Clinician Trustee on the Board of the Academy of Medical Royal Colleges, UK. He is also an honorary professor at the University of Birmingham Medical School, in recognition of his expertise in medicine development. He has the significant pharmaceutical industry experience and was the Head of Medical Research at AstraZeneca and the Research and Development Director at Ark Therapeutics Ltd, specializing in the development of gene therapy products.
He is a graduate in biochemistry and medicine from the University of Birmingham, UK.
This person is not in the org chart
This person is not in any offices
Taysha Gene Therapies
Taysha Gene Therapies is on a mission to eradicate severe and life-threatening monogenic CNS disease. With a singular focus on developing curative medicines, they hope to rapidly translate their treatments from bench to bedside.